Inflammatix
Inflammatix is a biotech firm that decodes immune responses to create diagnostic tests for acute infection, like its TriVerity system.
Secondary Market Price
How Inflammatix Measures Up
To help you manage your Inflammatix equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Inflammatix's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Inflammatix Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Inflammatix's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Inflammatix, Inc. is a biotechnology research company that develops diagnostic tests to analyze the body's immune response to acute infections and sepsis. The company uses bioinformatics, machine learning, and molecular biology to interpret immune system data, aiming to provide clinicians with rapid information for decision-making. Its primary product is the TriVerity test system, an FDA-cleared diagnostic that is being adopted in hospital emergency departments. Founded in 2016 by a team including CEO Tim Sweeney, the company is headquartered in Sunnyvale, California, and has an office in Lisboa, Portugal. Inflammatix has secured funding through multiple rounds, including a Series E round in October 2024 that raised $57 million.
Recent announcements from the company highlight the real-world implementation of its technology, such as the adoption of the TriVerity system at USA Health University Hospital in Alabama. The test was also recognized in the Stanford Department of Medicine’s 2024–2025 Annual Report as a notable development in sepsis care. Looking ahead, Inflammatix has expressed its intent to continue expanding the adoption of its current diagnostic systems while advancing its work in immune profiling. The company's stated goal is to further the application of precision medicine in acute care environments, with potential applications in guiding therapy selection.
- Khosla Ventures
- Think.Health
- Northpond Ventures
- D1 Capital Partners
- OSF Healthcare Ventures
- Co-Founder, Timothy Sweeney
- Co-Founder, Purvesh Khatri
- Co-Founder, Jonathan Romanowsky
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Inflammatix worth joining?
Deciding whether to join a company like Inflammatix involves evaluating your potential role, the company's trajectory, and the value of your equity compensation package. Tools like Prospect can help you model the potential financial outcomes of your equity to make a more informed decision.
What should I do with my Inflammatix stock?
Managing private stock options or RSUs requires a proactive strategy to maximize their value and minimize taxes, as inaction can be costly. Prospect offers customized strategies for exercising options and selling shares to help you make the best financial decisions for your situation.
Can you sell Inflammatix stock?
As a private company, selling Inflammatix stock is usually only possible during specific liquidity events like a tender offer or secondary sale. Platforms like Prospect provide tools to help you navigate these opportunities and determine the most tax-optimal shares to sell.
How can I find the value of my Inflammatix stock?
The value of private company stock is typically determined by its 409A valuation, but this doesn't reflect its future potential. Prospect uses predictive models to help you forecast your equity's future value based on market data and company growth signals.
What is Inflammatix's equity worth?
A private company's total equity value is typically based on its most recent funding round valuation, but an individual's holdings are what truly matter for personal wealth. You can use Prospect to model various scenarios and understand the potential net worth of your specific Inflammatix equity package.
What is Inflammatix's stock ticker symbol?
Inflammatix does not have a stock ticker symbol because it is a private company and its shares are not traded on a public stock exchange. A ticker symbol will only be assigned if the company undergoes an Initial Public Offering (IPO).
Can I buy or sell Inflammatix stock?
As Inflammatix is a private company, its stock is not available for purchase on the open market, and selling is typically restricted to company-approved liquidity events. For employees, Prospect can help manage the process of exercising options and selling shares when opportunities arise.
What is the criteria to buy or invest in Inflammatix stock?
Investing directly in a private company like Inflammatix is typically limited to venture capital firms and accredited investors participating in official financing rounds. For most individuals, the primary way to acquire equity is by becoming an employee and receiving it as part of a compensation package.
